Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5565 (Mirogabalin) in Fibromyalgia Pain
NCT02187471Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of mirogabalin in fibromyalgia (FM) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Average Daily Pain Score at 13 weeks. Started Jan 2015; status: completed.
02
Drugs
mirogabalin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT02187471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187471.